Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.
相关临床试验
16
4 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2006
进行中（未招募）
4
25.0%
已完成
11
68.8%
招募中
1
6.3%
暂无批准数据
- Anavex Life Sciences experienced a catastrophic 50% stock decline following the European Medicines Agency's negative trend vote on blarcamesine, its lead Alzheimer's disease drug candidate. - The CHMP rejection came after an oral hearing regarding the Marketing Authorization Application for the once-daily oral therapy targeting early Alzheimer's disease. - Despite the European setback, the FDA has advised Anavex to request a meeting to discuss clinical trial results, maintaining potential pathways for U.S. approval. - The stock dropped to $3.02 in premarket trading, representing a two-day decline of approximately 56% and pushing shares to their 52-week low.
- Anavex Life Sciences has successfully completed enrollment of 71 participants in its Phase 2 clinical study of ANAVEX®3-71 for schizophrenia treatment, with top-line data expected in the second half of 2025. - ANAVEX®3-71, a dual SIGMAR1 receptor agonist and M1 positive allosteric modulator, offers a novel mechanism that could potentially address all symptom domains of schizophrenia without the side effects of standard antipsychotics. - The trial addresses a significant unmet need in schizophrenia treatment, where approximately 34% of patients don't respond to current therapies and 50-60% experience only partial improvement or unacceptable side effects.
- Annovis Bio's buntanetap demonstrated significant improvements in cognitive function for early Parkinson's disease patients with mild dementia in a Phase III clinical trial, preventing cognitive decline compared to placebo. - While the drug failed to reach its primary endpoint in the total intention-to-treat population, subgroup analysis revealed that 20mg of buntanetap successfully improved both motor and cognitive functions in patients with MMSE scores of 20-26. - Buntanetap will compete with Anavex's blarcamesine and IRLAB Therapeutics' pirepemat in addressing cognitive complications in Parkinson's disease, targeting a significant unmet need identified by key opinion leaders.
- Alzheon is set to present Phase 3 trial data for ALZ-801 in April 2025, a drug designed to prevent the formation of toxic beta-amyloid plaques in early Alzheimer's patients with the ApoE4 gene. - Anavex Life Sciences has submitted blarcamesine for approval in Europe after completing Phase 2/3 trials, though its efficacy has faced criticism and legal challenges. - Athira Pharma discontinued fosgonimeton development after failing to demonstrate clinical benefit and settled with the DOJ over data manipulation allegations. - Eisai and Biogen's Leqembi may become more accessible with an injectable version under FDA review, potentially allowing for at-home administration.
• Anavex Life Sciences' blarcamesine demonstrates sustained cognitive and functional benefits in early Alzheimer's patients over three years of continuous oral treatment. • The European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for blarcamesine, a potential novel oral treatment for Alzheimer's disease. • Blarcamesine targets upstream Alzheimer's pathology through autophagy enhancement and has shown a favorable safety profile in clinical trials. • Anavex is also evaluating blarcamesine for other CNS indications, including Parkinson’s disease and Rett syndrome.
- Anavex Life Sciences' blarcamesine demonstrates significant reduction in clinical decline over three years for early Alzheimer's patients. - Delayed-start analysis reveals early treatment with blarcamesine leads to greater cognitive stability, highlighting the importance of early intervention. - The ATTENTION-AD trial confirms blarcamesine's favorable safety profile, with mostly mild to moderate adverse events and no treatment-related deaths. - Peer-reviewed data from a Phase IIb/III study published in JPAD supports blarcamesine's potential as a novel oral treatment for early Alzheimer's.
- The European Medicines Agency (EMA) has accepted Anavex's Marketing Authorization Application (MAA) for blarcamesine to treat Alzheimer's disease. - Anavex presented Phase IIb/III ATTENTION-AD Open-Label-Extension (OLE) trial data at the J.P. Morgan 2025 Healthcare Conference. - Preliminary Phase 2 clinical study results of ANAVEX3-71 for schizophrenia showed a dose-dependent effect on key EEG biomarkers. - Anavex reported a strong cash position of $132.2 million, anticipating a cash runway of approximately four years.
- Anavex Life Sciences Corp. reported a reduced net loss of $43.0 million for fiscal year 2024, driven by decreased operating expenses and increased other income. - The company's lead drug candidate, ANAVEX®2-73, showed significant improvements in cognitive and functional endpoints in a Phase 2b/3 trial for early Alzheimer's disease. - Clinical trials for ANAVEX®2-73 in Rett syndrome demonstrated significant improvements in behavioral symptoms and safety in both adult and pediatric populations. - Anavex is advancing ANAVEX®3-71 into clinical trials for schizophrenia, frontotemporal dementia, and Alzheimer's disease after successful Phase 1 safety trials.
• Over 120 Alzheimer's Disease treatment therapies are under development by 110+ companies globally, ranging from preclinical to marketed phases. • Emerging therapies like NRDN-201, ST-501, and KarXT are in various clinical trial phases, showing potential for significant market impact. • MapLight Therapeutics initiated a Phase 1 trial for ML-007/PAC, targeting schizophrenia and Alzheimer's disease psychosis, with Phase 2 trials planned. • The FDA granted conventional approval to Leqembi (lecanemab-irmb), marking the first amyloid beta-directed antibody to transition from accelerated approval.
• ShiraTronics has initiated its RELIEV-CM2 study, implanting its neuromodulation device in chronic migraine patients across the US and Australia to assess therapeutic effects. • QurAlis' QRL-201, designed to restore STATHMIN-2 expression, advances to the dose range-finding phase of its ANQUR trial for ALS after successful dose-escalation. • Anavex Life Sciences has submitted a marketing authorization application to the EU for blarcamesine as a potential treatment for Alzheimer's disease, based on Phase 2/3 trial data.
